Imatinib Is Not a Potential Alternative Treatment for Uterine Leiomyosarcoma
- 1 July 2005
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 11 (13) , 4977-4981
- https://doi.org/10.1158/1078-0432.ccr-04-2461
Abstract
Carta al editor.-- et al.Peer RevieweKeywords
This publication has 9 references indexed in Scilit:
- Prevalence of KIT Expression in Human TumorsJournal of Clinical Oncology, 2004
- c-Kit Expression in Patients with Uterine LeiomyosarcomasClinical Cancer Research, 2004
- Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KITGynecologic Oncology, 2003
- The proto-oncogene c-kit is expressed in leiomyosarcomas of the uterusGynecologic Oncology, 2003
- Lack of Expression of c-kit Protein (CD117) in Mesenchymal Tumors of the Uterus and OvaryInternational Journal of Gynecological Pathology, 2003
- Critical roles of c-Kit tyrosine residues 567 and 719 in stem cell factor–induced chemotaxis: contribution of src family kinase and PI3-kinase on calcium mobilization and cell migrationBlood, 2002
- An Immunohistochemical Analysis of Endometrial Stromal and Smooth Muscle Tumors of the gUterusThe American Journal of Surgical Pathology, 2002
- Immunohistochemical Staining for KIT (CD117) in Soft Tissue Sarcomas Is Very Limited in DistributionAmerican Journal of Clinical Pathology, 2002
- CD117 (KIT): A Diverse Protein With Selective Applications in Surgical PathologyAdvances in Anatomic Pathology, 2002